The GABAB receptor agonist AZD9343 inhibits transient lower oesophageal sphincter relaxations and acid reflux in healthy volunteers: A phase i study

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 9, 2009, Pages 937-946

  Beaumont, H ^a   Smout, A ^b   Aanen, M ^b   Rydholm, H ^c   Lei, A ^a   Lehmann, A ^c   Ruth, M ^c   Boeckxstaens, G ^a,d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; AZD 9343; BACLOFEN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE COMPARISON; ESOPHAGUS MANOMETRY; ESOPHAGUS PH; FOOD INTAKE; GASTROESOPHAGEAL REFLUX; HUMAN; LOWER ESOPHAGUS SPHINCTER; MALE; MULTICENTER STUDY; PARESTHESIA; PHASE 1 CLINICAL TRIAL; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; SWALLOWING; VOLUNTEER;

ADULT; BACLOFEN; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL SPHINCTER, LOWER; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; RECEPTORS, GABA-B; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349685069     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04107.x     Document Type: Article

References (41)

1. Heading RC. Prevalence of upper gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol Suppl 1999 231 : 3 8.
2. Locke GR III., Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997 112 : 1448 1456.
3. Glise H, Wiklund I. Health-related quality of life and gastrointestinal disease. J Gastroenterol Hepatol 2002 17 (Suppl S72 84.
4. Klinkenberg-Knol EC, Castell DO. Clinical spectrum and diagnosis of gastroesophageal reflux disease. In : Castell DO, ed. The Esophagus. Boston : Little, Brown, 1993 : 441 448.
5. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997 112 : 1798 1810.
6. Hatlebakk JG, Katz PO, Castell DO. Medical therapy. Management of the refractory patient. Gastroenterol Clin North Am 1999 28 : 847 860.
7. Dent J, Dodds WJ, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest 1980 65 : 256 267.
8. Dodds WJ, Dent J, Hogan WJ, et al. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med 1982 307 : 1547 1552.
9. Holloway RH. The anti-reflux barrier and mechanisms of gastro-oesophageal reflux. Baillieres Best Pract Res Clin Gastroenterol 2000 14 : 681 699.
10. Lehmann A. Inhibitors of transient lower esophageal sphincter relaxations ("Reflux inhibitors") in the future treatment of GERD. Gastroenterol Hepatol Annual Rev 2006 1 : 109 117.
11. Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 2000 118 : 7 13.
12. Lee KJ, Vos R, Janssens J, Tack J. Differential effects of baclofen on lower oesophageal sphincter pressure and proximal gastric motility in humans. Aliment Pharmacol Ther 2003 18 : 199 207.
13. Koek GH, Sifrim D, Lerut T, Janssens J, Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003 52 : 1397 1402.
14. Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003 17 : 243 251.
15. Zhang Q, Lehmann A, Rigda R, Dent J, Holloway RH. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2002 50 : 19 24.
16. Cange L, Johnsson E, Rydholm H, et al. Baclofen-mediated gastro-oesophageal acid reflux control in patients with established reflux disease. Aliment Pharmacol Ther 2002 16 : 869 873.
17. van Herwaarden MA, Samsom M, Rydholm H, Smout AJ. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Aliment Pharmacol Ther 2002 16 : 1655 1662.
18. Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 2003 52 : 464 470.
19. Grossi L, Spezzaferro M, Sacco LF, Marzio L. Effect of baclofen on oesophageal motility and transient lower oesophageal sphincter relaxations in GORD patients: a 48-h manometric study. Neurogastroenterol Motil 2008.
20. Partosoedarso ER, Young RL, Blackshaw LA. GABA(B) receptors on vagal afferent pathways: peripheral and central inhibition. Am J Physiol Gastrointest Liver Physiol 2001 280 : G658 68.
21. B receptor agonist and reflux inhibitor. Gastroenterology 2008 134 (suppl 1 A-131.
22. Holloway RH, Penagini R, Ireland AC. Criteria for objective definition of transient lower esophageal sphincter relaxation. Am J Physiol 1995 268 : G128 33.
23. Dent J, Holloway RH, Toouli J, Dodds WJ. Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastrooesophageal reflux. Gut 1988 29 : 1020 1028.
24. Penagini R, Schoeman MN, Dent J, Tippett MD, Holloway RH. Motor events underlying gastro-oesophageal reflux in ambulant patients with reflux oesophagitis. Neurogastroenterol Motil 1996 8 : 131 141.
25. Maniatis AG, Dalton CB, Brazer SR. High intrasubject variability in the measurement of postprandial reflux: is ambulatory pH monitoring reliable? Gastroenterology 1995 108 : A157.
26. Andrews PL, Wood KL. Systemic baclofen stimulates gastric motility and secretion via a central action in the rat. Br J Pharmacol 1986 89 : 461 467.
27. Blandizzi C, Colucci R, Carignani D, et al. Role of peripheral GABAB receptors in the regulation of pepsinogen secretion in anaesthetized rats. Eur J Pharmacol 1995 294 : 191 200.
28. Del TM, Blandizzi C, Bernardini MC. Central GABAA excitatory and GABAB inhibitory receptors regulate gastric acid secretion in rats. Eur J Pharmacol 1990 177 : 189 194. (Pubitemid 20088715)
29. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988 95 : 903 912.
30. Holloway RH, Dent J, Narielvala F, Mackinnon AM. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 1996 38 : 649 654.
31. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000 118 : 661 669.
32. Sontag SJ, Hirschowitz BI, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. Gastroenterology 1992 102 : 109 118.
33. Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001 120 : 1599 1606.
34. Barham CP, Gotley DC, Mills A, Alderson D. Precipitating causes of acid reflux episodes in ambulant patients with gastro-oesophageal reflux disease. Gut 1995 36 : 505 510.
35. van Herwaarden MA, Samsom M, Smout AJ. Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology 2000 119 : 1439 1446.
36. Pandolfino JE, Shi G, Trueworthy B, Kahrilas PJ. Esophagogastric junction opening during relaxation distinguishes nonhernia reflux patients, hernia patients, and normal subjects. Gastroenterology 2003 125 : 1018 1024.
37. Kahrilas PJ, Shi G, Manka M, Joehl RJ. Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia. Gastroenterology 2000 118 : 688 695.
38. Frazzoni M, De ME, Grisendi A, Savarino V. Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression. Aliment Pharmacol Ther 2002 16 : 881 886.
39. Gordon C, Kang JY, Neild PJ, Maxwell JD. The role of the hiatus hernia in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004 20 : 719 732.
40. Said A, Brust DJ, Gaumnitz EA, Reichelderfer M. Predictors of early recurrence of benign esophageal strictures. Am J Gastroenterol 2003 98 : 1252 1256.
41. Beaumont H, Boeckxstaens GE. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy? Am J Gastroenterol 2009 104 : 1764 1771.